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Effect of High-Dose Esomeprazole on CYP1A2, 
CYP2C19, and CYP3A4 Activities in Humans: 
Evidence for Substantial and Long-lasting 
Inhibition of CYP2C19
Taavi J. K. Kaartinen1,2, Aleksi Tornio1,2,3,4, Tuija Tapaninen1,2, Terhi Launiainen1, Nina Isoherranen5, 
Mikko Niemi1,2 and Janne T. Backman1,2,*
In vitro, esomeprazole is a time-dependent inhibitor of CYP2C19. Additionally, racemic omeprazole induces CYP1A2 
and omeprazole and its metabolites inhibit CYP3A4 in vitro. In this 5-phase study, 10 healthy volunteers ingested 
20 mg pantoprazole, 0.5 mg midazolam, and 50 mg caffeine as respective index substrates for CYP2C19, 3A4, and 
1A2 before and 1, 25, 49 (pantoprazole only), and 73 hours after an 8-day pretreatment with 80 mg esomeprazole 
twice daily. The area under the plasma concentration-time curve (AUC) of R-pantoprazole increased 4.92-fold (90% 
confidence interval (CI) 3.55–6.82), 2.31-fold (90% CI 1.85–2.88), and 1.33-fold (90% CI 1.06–1.68) at the 1-hour, 
25-hour, and 73-hour phases, respectively, consistent with a substantial and persistent inhibition of CYP2C19. The 
AUC of midazolam increased up to 1.44-fold (90% CI 1.22–1.72) and the paraxanthine/caffeine metabolic ratio up 
to 1.19-fold (90% CI 1.04–1.36), when the index substrates were taken 1 hour after esomeprazole. Based on the 
recovery of R-pantoprazole oral clearance, the turnover half-life of CYP2C19 was estimated to average 53 hours. 
Pharmacokinetic simulation based on the observed concentrations of esomeprazole and its metabolites as well 
as their published CYP2C19 inhibitory constants was well in line with the observed changes in R-pantoprazole 
pharmacokinetics during the course of the study. Extrapolations assuming linear pharmacokinetics of esomeprazole 
suggested weak to moderate inhibition at 20 and 40 mg twice daily dosing. In conclusion, high-dose esomeprazole 
can cause strong inhibition of CYP2C19, but only weakly inhibits CYP3A4 and leads to minor induction of CYP1A2. 
The enzymatic activity of CYP2C19 recovers gradually in ~ 3–4 days after discontinuation of esomeprazole 
treatment.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Esomeprazole and its metabolites are time-dependent in-
hibitors of CYP2C19 and some of its metabolites also inhibit 
CYP3A4. Some studies have suggested that esomeprazole in-
duces CYP1A2.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study investigated the effect of high-dose esomeprazole 
on CYP2C19, CYP1A2, and CYP3A4 activities in humans.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 High-dose esomeprazole causes a substantial, gradually de-
clining inhibition of CYP2C19, which lasts for at least 3 days, 
consistent with irreversible inhibition. Additionally, it causes 
a modest CYP3A4-inhibiting and CYP1A2-inducing effect. 
Using the recovery of R-pantoprazole oral clearance, the in vivo  
turnover half-life of CYP2C19 was approximated to be 
53 hours.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 Care is warranted if a CYP2C19 substrate drug is used con-
comitantly or within a few days after discontinuation of esome-
prazole. Esomeprazole’s effect on CYP3A4 and 1A2 can be 
clinically relevant for their substrates with narrow therapeutic 
index. The turnover half-life estimate will be useful in in vitro-
in vivo extrapolations and physiologically-based pharmacoki-
netic modeling of CYP2C19 mediated drug-drug interactions.
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Proton pump inhibitors (PPIs) are extensively used to treat stom-
ach acid-related disorders and they are generally well-tolerated.1 
However, their pharmacokinetics vary considerably due to genetic 
polymorphisms of cytochrome P450 (CYP) 2C19.2 Moreover, 
they cause drug-drug interactions (DDIs) by altering drug absorp-
tion via increasing gastric pH, and particularly omeprazole and its 
S-enantiomer esomeprazole, by affecting drug metabolism.
Racemic omeprazole and esomeprazole are clinically relevant 
inhibitors of CYP2C19. In addition, they have been suspected 
to have an effect on CYP3A4 and CYP1A2 activities. Although 
R-omeprazole inhibits CYP2C19 reversibly, racemic omeprazole 
and esomeprazole inhibit it metabolism-dependently in vitro.3 In 
clinical trials, 80 mg omeprazole or 40 mg esomeprazole daily have 
markedly reduced the CYP2C19-mediated formation of clopi-
dogrel’s active metabolite and reduced its antiplatelet effect,4,5 
and modestly raised the plasma concentrations of some other 
CYP2C19 substrates.6
In vitro, omeprazole and its metabolites inhibit CYP3A4.7,8 In 
addition, both omeprazole and particularly esomeprazole can acti-
vate the pregnane X and aryl hydrocarbon receptors9,10 and might, 
therefore, also induce CYP3A4 and CYP1A2 expression. Based 
on small clinical studies, standard doses of racemic omeprazole 
slightly increase the concentrations of the CYP3A4 substrates car-
bamazepine and nifedipine11,12 suggesting a net inhibitory effect 
on CYP3A4. Furthermore, clinical trials suggest that racemic ome-
prazole has a weak CYP1A2 inducing effect in poor metabolizers 
of CYP2C19 and when used at high doses.13,14 However, clinical 
studies of the effects of esomeprazole on CYP3A4 or CYP1A2 ac-
tivities are sparse and conclusive evidence is lacking. For example, 
although standard doses of esomeprazole increased the area under 
the plasma concentration-time curve (AUC) of the CYP3A4 sub-
strate cisapride, it had no effect on the pharmacokinetics of clar-
ithromycin or quinidine, and, in one study, in CYP2C19 poor 
metabolizers, it had no effect on CYP1A2 activity.15
It is important to fully understand the PPIs’ effects on 
CYP2C19, CYP3A4, and CYP1A2, because PPIs are frequently 
co-administered with many substrates of these CYP enzymes. It is 
recommended that sensitive index substrates and the highest clin-
ically used doses of the perpetrator drug should be used in clinical 
DDI studies to characterize the DDI potential of the perpetrator 
drug.16 Accordingly, in the case of esomeprazole, the worst-case 
scenario of its enzyme inhibiting and inducing effects could proba-
bly be best estimated by using the high 160 mg daily doses that are 
occasionally required in Zollinger-Ellison syndrome. For CYP1A2 
and CYP3A4, several sensitive index substrates are available, but 
for CYP2C19, PPIs are the most sensitive. Apart from omeprazole, 
particularly the R-isomer of pantoprazole could be a sensitive index 
substrate.17
As esomeprazole is a metabolism-dependent inhibitor of 
CYP2C19 in vitro,3 it is likely that high-dose esomeprazole causes 
a stronger and more persistent inhibition of CYP2C19 than what 
has been previously observed when using lower esomeprazole 
doses. Because metabolism-dependent inhibition causes a perma-
nent loss of the enzyme’s activity,18 the recovery of the metabolic 
function after stopping the treatment with the inhibitor requires 
de novo synthesis of new enzyme. Accordingly, the time needed to 
reach new steady-state in enzyme activity depends on the enzyme’s 
specific turnover half-life.19 The turnover of CYP2C19 is poorly 
characterized, however. The predicted strong metabolism-depen-
dent inhibition of CYP2C19 with high-dose esomeprazole and 
esomeprazole’s relatively short plasma half-life of 1–2 hours pro-
vide an excellent opportunity to determine the turnover half-life of 
CYP2C19 in humans.
The objective of this study was to assess the extent of the in-
hibitory and inducing effects of esomeprazole on CYP2C19, 
CYP3A4, and CYP1A2 activities in healthy volunteers after a pre-
treatment with the highest clinically used daily dose of esomepra-
zole using pantoprazole, midazolam,20 and caffeine as respective in 
vivo index substrates (Figure S1). The recovery of pantoprazole 
clearance after stopping esomeprazole dosing was also examined, 
in order to estimate the turnover half-life of CYP2C19 and to 




Ten healthy volunteers (5 men and 5 women) were enrolled in the study. 
All participants gave a written informed consent before any study pro-
cedures were performed. Their health was confirmed by medical his-
tory, clinical examination, and routine laboratory tests before entering 
the study. None of the participants were smokers or used any contin-
uous medications (e.g., hormonal contraceptives). The subjects were 
genotyped for the CYP2C19 alleles *2, *3, *8, and *17, as decribed in 
Supplementary Methods.
Study design
The study protocol was approved by the Coordinating Ethics 
Committee of the Helsinki and Uusimaa Hospital District (record num-
ber 57/13/03/00/2015) and by the Finnish Medicines Agency Fimea 
(EudraCT number 2015-000367-13). A 5-phase fixed-order crossover 
study was carried out (Figure S1). In the control phase (day 1), the par-
ticipants ingested a 20-mg dose of racemic pantoprazole (Somac 20-mg 
enteric-coated tablet; Leiras Takeda, Oranienburg, Germany), a 50-mg 
dose of caffeine (half of a 100-mg tablet of Coffein Etnovia; Etnovia Oy, 
Seinäjoki, Finland), and 0.5-mg dose of midazolam (0.5 mL of Midazolam 
Accord 1 mg/mL Solution; Accord Healthcare Limited, Middlesex, UK) 
with 150 mL of water at 9 am as probe drugs for CYP2C19, CYP1A2, and 
CYP3A4 activities, respectively. After finishing the control phase, the par-
ticipants were given a pretreatment with 80 mg esomeprazole (two Nexium 
40-mg enteric-coated tablets; AstraZeneca AB, Södertälje, Sweden) twice 
daily at 8 am and 8 pm on days 2–8 with the last dose administered at 8 
am on day 9. Thereafter, the participants were administered 20 mg pan-
toprazole, 50 mg caffeine, and 0.5 mg midazolam with 150 mL of water 1, 
25, and 73 hours after the last esomeprazole dose (days 9, 10, and 12). In 
addition, 20 mg pantoprazole was administered after 49 hours (day 11), to 
allow estimation of the AUC of pantoprazole and modeling of the recov-
ery of CYP2C19 activity over the course of the study. After an overnight 
fast, a standard warm meal and snack were served 3 and 7 hours after the 
administration of pantoprazole. Alcohol consumption was prohibited for 
1 day prior to and during the study days, and caffeine consumption from 
9 pm before the days of caffeine administration. The participants were not 
permitted to consume grapefruits or grapefruit products or use any other 
medications for 1 week prior to and during the study.
Sampling
Timed blood samples (4 or 9  mL each) were drawn 5  minutes before 
and 20  minutes, 40  minutes, and 1, 1.5, 2, 3, 4, 5, and 7  hours after 
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pantoprazole administration in the control phase and on the days when 
pantoprazole was administered 1, 25, or 73 hours after the last esomepra-
zole dose. A blood sample was also drawn just before the administration 
of the last esomeprazole dose. On the day pantoprazole was administered 
49  hours after the last esomeprazole dose, blood samples were drawn 
only 5 minutes before, and 2 and 7 hours after pantoprazole ingestion. 
The samples were drawn in tubes containing ethylenediaminetetraacetic 
acid and placed on ice immediately after sampling. Plasma was separated 
within 30 minutes and stored in −70°C until analysis.
Pharmacokinetics
Methods for determination of drug concentrations are described in 
Supplementary Methods and Table S1. The following pharmacoki-
netic variables were calculated for pantoprazole, midazolam, and their 
metabolites by standard noncompartmental methods using Phoenix 
WinNonlin, version 6.4 (Certara, Princeton, NJ): peak plasma concen-
tration (Cmax), time to Cmax (Tmax), AUC from 0–7 hours (AUC0–7 h), 
AUC from 0  hours to infinity (AUC0–∞), and terminal half-life (t1/2). 
Furthermore, the Cmax, t1/2, and fractional AUCs corresponding to 
each phase after the last dose of esomeprazole (AUC0–8 h, AUC25–32 h, 
AUC49–56 h, and AUC73–80 h) were calculated for esomeprazole and its 
metabolites. The oral clearances of the enantiomers of pantoprazole were 
calculated by first dividing the oral dose of racemic pantoprazole (20 mg) 
by two and then by their respective AUC0–∞ values. To assess CYP1A2 
activity, the paraxanthine/caffeine ratio was calculated from a blood 
sample taken 5 hours after caffeine dosing.21
Statistical analysis
Ten subjects were estimated to be adequate to detect a 30% change in 
AUC0–∞ between the control and the following phases with a power of 
at least 80% (α level 5%). The results are expressed as geometric means 
and geometric mean ratios with geometric coefficient of variations or 90% 
confidence intervals (CIs), unless otherwise stated. All pharmacokinetic 
variables, except Tmax, were logarithmically transformed before statistical 
analysis. The pharmacokinetic variables were compared by repeated-mea-
sures analysis of variance with the study phase as a within-subjects factor, 
with pairwise comparisons with the Fisher’s least significant difference 
method. P values < 0.05 were considered statistically significant. Wilcoxon 
signed rank test was used for comparisons of Tmax. Statistical analyses were 
carried out using IBM SPSS Statistics for Mac OS (version 24.0.0.0; IBM, 
Armonk, NY).
Estimation of CYP2C19 enzyme turnover half-life
The CYP2C19 enzyme turnover half-life was estimated by regression 
analysis, using the recovery of the oral clearances of R-pantoprazole after 
esomeprazole administration, as described previously (Supplementary 
Methods).22
Simulation of CYP2C19 activity following esomeprazole 
dosing
The time course of CYP2C19 inhibition during the study was mod-
eled using dynamic methods and numerical solutions, as previously 
described (Supplementary Methods and Table S2) and carried out in 
MS Excel for Mac (version 16.36, Microsoft, Redmont, WA).23 For the 
simulations, the degradation half-life of CYP2C19 was set as 53 hours 
(0.0131  hr-1) and the liver CYP2C19 expression level in the baseline 
condition was assumed to be 14 pmol/mg microsomes.24 The previously 
published7 reversible and time-dependent inhibition kinetic values for 
racemic omeprazole and its metabolites were used to predict the time 
course and magnitude of CYP2C19 inhibition. The KI-values for each 
compound were corrected for the competition of binding by other cir-
culating compounds, as previously described,25 and the overall effect 
on CYP2C19 activity was predicted simultaneously accounting for 
esomeprazole and its metabolites assuming the inactivation followed an 
additive model.25 For modeling purposes, the observed plasma concen-
trations of esomeprazole and its metabolites during the dose interval on 
the last day of the pretreatment were used throughout the time course 
of the simulation for each administered dose (interval). For each time 
point, the unbound concentrations of each compound were calculated 
based on previously reported plasma unbound fractions.7 The observed 
minor accumulation of the metabolites, particularly the sulfone, was 
not considered in the quantitative predictions. In addition, assuming 
linear pharmacokinetics of esomeprazole, extrapolations for 40  mg or 
20  mg twice daily dosing regimens were made by multiplying the ob-




Esomeprazole increased R-pantoprazole AUC0–∞ 4.92-fold 
(P < 0.001), 2.31-fold (P < 0.001), and 1.33-fold (P < 0.05) com-
pared with the control when pantoprazole was administered 1, 
25, and 73  hours after the last esomeprazole dose, respectively 
(Figure 1b, Figure 2a, Table 1). S-pantoprazole AUC0–∞ was 
increased 2.05-fold (P  <  0.005) and 1.63-fold (P  <  0.05) in the 
1 and 25 hour phases, respectively (Figure 1a, Table 1), whereas 
the AUC0–∞ was not significantly increased in the 73 hour phase. 
In the 1, 25, and 73 hour phases, the Cmax of R-pantoprazole was 
increased 2.68-fold (P  <  0.001), 1.97-fold (P  <  0.05), and 1.53-
fold (P  <  0.05), and t1/2 was prolonged from 0.8 to 2.7  hours 
(P  <  0.001), 1.4  hours (90% CI, 1.5–2.0-fold; P  <  0.001), and 
1.0  hours (P  <  0.001), respectively. The Cmax of S-pantoprazole 
was increased 1.90-fold (P < 0.05) and 1.60-fold (P < 0.05) in the 
1 and 25 hour phases. The t1/2 of S-pantoprazole was prolonged 
from 1.0 to 1.6  hours (P  <  0.001), 1.4  hours (P  <  0.001), and 
1.2 hours (P < 0.005) in the 1, 25, and 73-hour phases, respectively.
Pharmacokinetics of midazolam
Esomeprazole increased midazolam AUC0–∞ 1.44-fold 
(P  <  0.005) and Cmax 1.59-fold (P  <  0.005), when midaz-
olam was administered 1 hour after esomeprazole (Figure 1c, 
Figure 2b, Table 1). The corresponding 1′-hydroxymidazolam/
midazolam AUC0–∞-ratio was decreased to 77% of control 
(P < 0.001; Figure 2c). Esomeprazole had no significant effect 
on the t1/2 of midazolam. No significant changes in the pharma-
cokinetics of midazolam or 1′-hydroxymidazolam were observed 
compared with control, when midazolam was administered 25 
or 73 hours after esomeprazole, except for a 35% increase in the 
Cmax of midazolam in the 73-hour phase (P < 0.05).
Paraxanthine/caffeine ratio
The paraxanthine/caffeine concentration ratio was increased 
1.19-fold (P  <  0.05; Figure 2d, Table 1) when caffeine was in-
gested 1 hour after the last dose of esomeprazole, but the ratio was 
not significantly increased at later time points.
Pharmacokinetics of esomeprazole
The Cmax of esomeprazole and its metabolites after the last es-
omeprazole dose occurred at 1.7–3.0 hours (Figure 3, Table 2). 
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At 25 hours after the last esomeprazole dose, the plasma concen-
trations of esomeprazole had decreased below the detection limit 
(10 ng/mL; i.e., to < 1% of the average Cmax in each subject). At 
25 hours, the mean concentrations of 5’-O-desmethylomeprazole 
sulfide and omeprazole sulfone were 4.6% and 3.1% of their peak, 
respectively, and the other metabolite concentrations were ≤ 1% of 
their peak (Figure 3).
CYP2C19 genotypes
There was a trend toward a larger increase in the exposure to 
R-pantoprazole in subjects with higher activity CYP2C19-
genotypes (*1/*17 and *1/*1) than in subjects with the *1/*2 
genotype, with a 16.6-fold increase in the AUC0–∞ of R-
pantoprazole in one subject with the CYP2C19*1/*17 gen-
otype (Figure 4, Table S3). However, no association was 
evident between CYP2C19-genotypes and AUC values of es-
omeprazole or S-pantoprazole. No formal statistical compari-
sons were performed between the genotype groups due to the 
small sample size.
CYP2C19 turnover half-life and simulation of the time 
course of CYP2C19 activity
The estimated CYP2C19 turnover half-life was 53.3  hours 
based on pooled data of all subjects after exclusion of one sub-
ject whose individual data had poor statistical fit. When the 
subjects were analyzed separately, the geometric mean turnover 
half-life was 49.5  hours (Figure 5, Table S3). When the time 
course of CYP2C19 activity following esomeprazole dosing was 
simulated based on the concentrations of esomeprazole and its 
metabolites and published in vitro CYP2C19 inhibitory activity 
of racemic omeprazole and its metabolites,7 the simulated mag-
nitude of CYP2C19 inhibition and the time course of recovery 
of CYP2C19 activity were in good agreement with the observed 
data of R-pantoprazole clearance (Figure 5).
DISCUSSION
This study showed that high-dose esomeprazole treatment 
leads to substantial, from moderate to strong inhibition of 
CYP2C19, resulting in an average fivefold increase in the AUC 
Figure 1 The plasma concentrations of pantoprazole enantiomers, midazolam and 1′-hydroxymidazolam. The panels show the geometric 
mean plasma concentrations with 90% confidence intervals of (a) S-pantoprazole and (b) R-pantoprazole, (c) midazolam and its metabolite 
(d) 1′-hydroxymidazolam following a single-dose of 20 mg of racemic pantoprazole and 0.5 mg of midazolam at 9 am in 10 healthy volunteers. 
Pantoprazole was administered before (control) and 1, 25, 49, and 73 hours after, and midazolam before and 1, 25, and 73 hours after the 
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of the R-enantiomer of pantoprazole. Of note, the increases in R-
pantoprazole AUC were more than fivefold in most individuals 
who were rapid or normal CYP2C19 metabolizers (noncarriers 
of the no-function CYP2C19 alleles). Albeit smaller, the effect 
of esomeprazole on pantoprazole persisted until 73  hours after 
esomeprazole dosing. In addition, esomeprazole slightly raised 
the plasma concentrations of the CYP3A4-substrate midazolam 
and the paraxanthine/caffeine ratio, an index of CYP1A2 activ-
ity, when midazolam and caffeine were administered 1 hour after 
esomeprazole.
According to in vitro-in vivo extrapolations, the inhib-
itory effect of racemic omeprazole on CYP2C19 is to a large 
extent explained by time-dependent inhibition by parent 
omeprazole and its metabolites omeprazole sulfone and 5′-O-
desmethylomeprazole,3,7 which have been estimated to con-
tribute by about 70%, 5%, and 25% to the total CYP2C19 
inhibition, respectively.7 The simulations and the concentra-
tions measured in this high-dose study predicted that esomepra-
zole contributes only 50% to the total CYP2C19 inactivation, 
whereas the sulfone and desmethylomeprazole contribute about 
20–30% each (data not shown). This is likely due to the non-
linear kinetics of esomeprazole and subsequent different metab-
olite-to-parent ratios at different doses; due to autoinhibition 
of the CYP2C19-mediated metabolism of omeprazole, the 
proportion of the CYP3A4-dependent omeprazole sulfone in-
creases dose-dependently and time-dependently.26 Additionally, 
according to in vitro and clinical studies, the sulfone metabolite 
is quantitatively more important in the metabolism of esomepra-
zole than in that of racemic omeprazole.27,28 In turn, metabolites 
of omeprazole have been estimated to account for > 60% of the 
inhibition of CYP3A4, mainly due to metabolism-dependent 
inactivation of CYP3A4 by 5′-O-desmethylomeprazole and pos-
sibly reversible CYP3A4 inhibition by 5′-hydroxyomeprazole.7
In the present study, the inhibitory effect of esomeprazole on 
CYP2C19 was relatively strong at 25  hours after esomeprazole 
dosing, even though the concentrations of the main CYP2C19 in-
hibiting compounds esomeprazole and 5′-O-desmethylomeprazole 
had decreased to < 1% of their peak and those of omeprazole sul-
fone to about 3% of its peak. As also observed in the simulation, 
it is likely that the inactivation process of CYP2C19 had ceased 
practically completely and that the direct inhibitory effects of es-
omeprazole and its metabolites were not clinically relevant at that 
time. Accordingly, the present results demonstrate that esome-
prazole can cause a long-lasting inhibitory effect on CYP2C19, 
consistent with an irreversible or mechanism-based inhibitory 
effect on CYP2C19. As the recovery of enzyme activity after 
Figure 2 The area under the plasma concentration-time curve from zero to infinity (AUC0-∞) of R-pantoprazole and midazolam, the AUC0-∞  
ratio of 1’-hydroxymidazolam/midazolam and the paraxanthine/caffeine concentration ratio over the course of the study. The panels 
show the geometric mean and individual body weight adjusted (to 70 kg) AUC0-∞ values of (a) R-pantoprazole and (b) midazolam, (c) the 
1′-hydroxymidazolam/midazolam AUC0-∞ ratio, and (d) the 5-hour postdose paraxanthine/caffeine concentration ratio before and after the last 
esomeprazole dose. A 20-mg dose of pantoprazole was administered before (control) and 1, 25, 49, and 73 hours after, and a 0.5-mg dose 
of midazolam and a 50-mg dose of caffeine before and 1, 25, and 73 hours after an 8-day pretreatment with 80 mg esomeprazole twice daily. 
Individual data are denoted with different symbols, and geometric means are connected with a solid line between study phases. * P < 0.05 
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Table 1 Pharmacokinetic variables of pantoprazole, midazolam and 1′-OH-midazolam following a single 20-mg oral dose of 
pantoprazole and a single 0.5-mg oral dose midazolam in 10 healthy subjects after the last dose of an 8-day pretreatment 
with a 80-mg dose of esomeprazole twice daily, when pantoprazole was administered 1, 25, or 73 hours after the last 
esomeprazole dose
Variable Control
Time from the last esomeprazole dose
1 hour 25 hours 73 hours
S-pantoprazole
Cmax, ng/mL 495 (69) 943 (28)* 789 (27)* 689 (42)
† 
Ratio to control, 90% CI – 1.90 (1.29–2.80) 1.60 (1.11–2.30) 1.39 (1.04–1.86)
t1/2, hours 1.0 (18) 1.6 (15)*** 1.4 (18)***
,† 1.2 (13)**,†††,‡‡ 
Ratio to control, 90% CI – 1.60 (1.42–1.82) 1.36 (1.22–1.52) 1.22 (1.11–1.34)
AUC0-7 h, ng·h/mL 1275 (67) 2489 (26)** 2047 (31)*
,† 1605 (46)††,‡‡ 
Ratio to control, 90% CI – 1.95 (1.40–2.73) 1.60 (1.23–2.09) 1.26 (0.99–1.60)
AUC0-∞, ng·h/mL 1351 (65) 2771 (27)** 2205 (33)*
,†† 1708 (47)†††,‡‡‡ 
Ratio to control, 90% CI – 2.05 (1.48–2.85) 1.63 (1.26–2.11) 1.26 (1.00–1.60)
R-pantoprazole
Cmax, ng/mL 387 (66) 1037 (26)*** 761 (31)*
,† 592 (45)*,†††,‡‡ 
Ratio to control, 90% CI – 2.68 (1.87–3.84) 1.97 (1.40–2.78) 1.53 (1.12–2.08)
t1/2, hours 0.8 (20) 2.7 (21)*** 1.4 (26)***
,††† 1.0 (16)***,†††,***,‡‡‡ 
Ratio to control, 90% CI – 3.25 (2.80–3.76) 1.76 (1.54–1.99) 1.26 (1.15–1.38)
AUC0-7 h, ng·h/mL 886 (66) 3390 (24)*** 1916 (32)***
,††† 1171 (56)*,†††,‡‡‡ 
Ratio to control, 90% CI – 3.83 (2.77–5.28) 2.16 (1.73–2.71) 1.32 (1.05–1.66)
AUC0-∞, ng·h/mL 916 (65) 4504 (28)*** 2113 (38)***
,††† 1219 (57)*,†††, ‡‡‡ 
Ratio to control, 90% CI – 4.92 (3.55–6.82) 2.31 (1.85–2.88) 1.33 (1.06–1.68)
Midazolam
Cmax, ng/mL 2.07 (29) 3.31 (38)** 2.50 (27)
† 2.81 (37)*,†
Ratio to control, 90% CI – 1.59 (1.31–1.96) 1.21 (1.02–1.43) 1.35 (1.08–1.69)
t1/2, hours 1.5 (9.2) 1.4 (14) 1.5 (4.8) 1.5 (13)
Ratio to control, 90% CI – 0.90 (0.82–0.99) 0.96 (0.91–1.01) 0.94 (0.86–1.03)
AUC0-7 h, ng·h/mL 4.49 (26) 6.38 (28)*** 4.93 (26)
††† 5.18 (31)‡‡ 
Ratio to control, 90% CI – 1.42 (1.23–1.64) 1.10 (0.94–1.28) 1.15 (0.99–1.34)
AUC0-∞, ng·h/mL 4.72 (27) 6.82 (31)** 5.23 (30)
††† 5.39 (32)††† 
Ratio to control, 90% CI – 1.44 (1.22–1.72) 1.11 (0.93–1.32) 1.14 (0.97–1.34)
1′-OH-Midazolam
Cmax, ng/mL 1.21 (34) 1.39 (42) 1.23 (47) 1.35 (39)
Ratio to control, 90% CI – 1.15 (0.94–1.41) 1.02 (0.83–1.25) 1.12 (0.93–1.34)
t1/2, hours 1.4 (20) 1.3 (16) 1.4 (21) 1.5 (12)
Ratio to control, 90% CI – 0.96 (0.88–1.04) 0.98 (0.88–1.08) 1.05 (0.97–1.14)
AUC0-7 h, ng·h/mL 2.57 (29) 2.89 (36) 2.54 (41) 2.72 (33)
Ratio to control, 90% CI – 1.13 (0.98–1.30) 0.99 (0.81–1.21) 1.06 (0.92–1.22)
AUC0-∞, ng·h/mL 2.67 (29) 2.98 (36) 2.64 (42) 2.84 (33)
Ratio to control, 90% CI – 1.12 (0.97–1.29) 0.99 (0.80–1.21) 1.06 (0.92–1.23)
1′-OH-M/M AUC0-7 h ratio 0.57 (24) 0.45 (22)*** 0.52 (25)
† 0.53 (30)† 
Ratio to control, 90% CI – 0.79 (0.72–0.87) 0.90 (0.80–1.02) 0.92 (0.82–1.04)
1′-OH-M/M AUC0-∞ ratio 0.57 (24) 0.44 (21)*** 0.50 (24)
† 0.53 (30)†
Ratio to control, 90% CI – 0.77 (0.71–0.85) 0.89 (0.80–0.99) 0.93 (0.83–1.05)
 (Continued)
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mechanism-based inhibition occurs by de novo synthesis of the en-
zyme, likely occurring at a constant rate, it was possible to calculate 
the in vivo turnover half-life of CYP2C19, giving an estimate of 
~ 53 hours.
Mainly based on in vitro data and indirect in vivo models, the 
turnover half-lives of CYP enzymes have generally been estimated 
to range from 23–140 hours,18 showing large differences between 
enzymes and methods used. For example, the in vivo estimates of 
CYP3A4 turnover half-life have ranged from 70–140  hours,19 
whereas that of CYP2C8 has been only 22 hours.22 However, in 
vivo data concerning the turnover of some other CYPs, such as 
CYP2C19, have been sparse. A small study with human hepatic 
slices from three nonrelated livers suggested that the half-life of 
CYP2C19 is between 7 and 50 hours.29 Our estimated CYP2C19 
Figure 3 The geometric mean plasma concentrations with 90% confidence intervals of esomeprazole and its metabolites after the last dose 
of an 8-day pretreatment with 80 mg of esomeprazole twice daily. (a) Esomeprazole, (b) 5′-O -desmethyl-omeprazole, (c) 5′-OH-omeprazole, (d) 

































































































































































1.17 (24) 1.39 (16)* 1.41 (17) 1.17 (14)
Ratio to control, 90% CI – 1.19 (1.04–1.36) 1.20 (1.01–1.42) 1.00 (0.87–1.14)
Data are given as geometric mean with geometric coefficient of variation. The geometric mean ratios between the two phases are given with 90% CI.
AUC0-7 h, area under the plasma concentration-time curve from time 0 to 7 hours; AUC0-∞, area under the plasma concentration-time curve from time 0 to infinity; 
CI, confidence interval; Cmax, peak plasma concentration; t1/2, elimination half-life.
*P < 0.05 vs. control.
**P < 0.005 vs. control.
***P < 0.001 vs. control.
 †P < 0.05 vs. 1 hour.
 ††P < 0.005 vs. 1 hour.
 †††P < 0.001 vs. 1 hour.
 ‡P < 0.05 vs. 25 hours.
 ‡‡P < 0.005 vs. 25 hours.
 ‡‡‡P < 0.001 vs. 25 hours.
Table 1 (Continued)
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half-life of 53 hours is longer than these in vitro values and likely 
to be more useful in modeling of CYP2C19 inhibition and induc-
tion. Moreover, this result suggests that CYP2C19 activity recovers 
slower than that of the structurally related CYP2C822 and compa-
rably with, for example, CYP1A2, CYP2D6, and CYP2E1.19
Our findings implicate markedly stronger inhibition of 
CYP2C19 by esomeprazole than what has been observed pre-
viously with smaller esomeprazole doses. In the previous studies, 
the greatest alteration in the AUC value of a CYP2C19 substrate 
caused by esomeprazole (30 mg daily) has been a 1.8-fold increase 
in diazepam exposure.15 For comparison, 40 mg racemic omepra-
zole has increased the AUC of diazepam 2.2-fold,30 and that of 
moclobemide 2.2-fold in normal CYP2C19 metabolizers.31 The 
stronger effect of esomeprazole seen in the present study is mainly 
explained by the 4–5 times higher 160 mg daily dose used. In ad-
dition, pantoprazole is likely a more sensitive CYP2C19 index 
substrate than diazepam or moclobemide, allowing even 5-fold to 
10-fold increases in the AUC to occur.16
Based on pharmacogenetic studies comparing normal and poor 
metabolizers of CYP2C19, it can be estimated that the average 
contribution of CYP2C19 to R-pantoprazole clearance is > 85% 
in normal metabolizers.17,32 Our dynamic model suggested that, 
during the 80 mg twice daily dosing, esomeprazole causes about 
75% inhibition of CYP2C19, and full recovery of CYP2C19 
activity can be obtained within 1 week after stopping the treat-
ment. An extrapolated simulation with the more commonly 
used doses of 40 mg and 20 mg twice daily predicted about 60% 
and 40% inhibition of CYP2C19 at steady-state, respectively. 
However, because we had to assume linear pharmacokinetics of 
esomeprazole, as no sufficient pharmacokinetic data of esome-
prazole and its metabolites at lower doses were available, these 
extrapolations should be interpreted with caution. Although the 
simulated time-course of CYP2C19 activity after 80  mg twice 
daily dosing was generally in very good agreement with the ob-
served changes in R-pantoprazole clearance, particularly during 
recovery of CYP2C19 activity, the simulations cannot fully ex-
plain the changes in R-pantoprazole pharmacokinetics, even if 
Figure 4 The individual fold increases in the area under the 
plasma concentration-time curve from zero to infinity (AUC0-∞) of 
S-pantoprazole and R-pantoprazole following administration of 20 mg 
of racemic pantoprazole 1 hour after the last esomeprazole dose. 
Pantoprazole was administered 1 hour after the last dose of an 
8-day pretreatment with 80 mg of esomeprazole twice daily. In the 
control phase, pantoprazole was administered without pretreatment. 
CYP2C19 genotypes are indicated with the following symbols: 
circle and solid lines for *1/*2, squares for *1/*1, and triangles 
for *1/*17. R-pantoprazole was more sensitive to alterations in 
CYP2C19 activity and its ratios ranged from 2.5-fold to 16.6-fold 















































Table 2 Pharmacokinetic variables of esomeprazole (S-OME) and its metabolites 5’-O-desmethyl-omeprazole (5-O-dmet-
OME), 5’-OH-omeprazole (5-OH-OME), omeprazole sulfone (OME-SO2), omeprazole sulfide (OME-S), and 5’-O-desmethyl-
omeprazole sulfide (5-O-dmet-OME-S) after the last dose of an 8-day pretreatment with 80 mg of esomeprazole twice daily
Cmax, ng/mL Tmax, hour t1/2, hour










S-OME 3,360 (30) 1.66 (1.33–2.5) 1.2 (14) 8,410 (28) 8,570 (28) 0.00 0.00 0.00
5-O -dmet-OME 86.0 (29) 1.66 (1.33–2.0) 1.4 (13) 241 (21) 250 (20) 0.00 0.00 0.00
5-OH-OME 135 (30) 1.66 (1.33–3.0) 1.7 (20) 431 (30) 456 (31) 0.02 (660) 0.00 0.00
OME-SO2 1,435 (18) 3.00 (2.0–4.0) 4.1 (18) 8,353 (16) 13,380 (23) 158.6 (100) 2.27 (250) 0.04 (1200)
OME-S 18.3 (36) 2.50 (1.33–3.0) 2.9 (39) 59.6 (37) 70.3 (36) 0.15 (2,900) 0.00 0.00
5-O -dmet-OME-S 3.37 (60) 1.83 (1.33–2.5) 7.8 (40) 10.5 (50) 17.1 (44) 0.74 (44) 0.09 (200) 0.01 (970)
Data are given as geometric mean with geometric coefficient of variation (CV%) except for Tmax, which is given as median with range.
AUC0-∞, area under the plasma concentration-time curve from zero to infinity; AUC0-8 h, area under the plasma concentration-time curve from zero to 8 hours; 
AUC25-32 h, area under the plasma concentration-time curve from 25 to 32 hours; AUC46-56 h, area under the plasma concentration-time curve from 46 to 
56 hours; AUC73-80 h, area under the plasma concentration-time curve from 73 to 80 hours; Cmax, peak plasma concentration; Tmax, time to peak plasma 
concentration; t1/2, terminal half-life.
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the contribution of CYP2C19 to its clearance was almost 100%. 
In the present simulations, we used racemic omeprazole’s inhi-
bition constants. Thus, a possible explanation for this is that es-
omeprazole is a stronger time-dependent inhibitor of CYP2C19 
than R-omeprazole, as suggested by previous in vitro findings.3 
Moreover, the unbound concentrations of esomeprazole in he-
patocytes could be higher during its absorption phase than those 
in peripheral plasma. In addition, it is possible that the CYP3A4 
inhibitory effect of esomeprazole contributed to the net effect 
on R-pantoprazole metabolism when pantoprazole was given 
1 hour after esomeprazole.
As the effects on midazolam and caffeine were evident in their 
metabolic ratios, our findings indicate that esomeprazole slightly 
inhibits CYP3A4 and induces CYP1A2, and that the effects were 
not driven by, for example, changes in gastric pH. Previously, 40 mg 
or 30 mg esomeprazole daily has had no significant effect on the 
pharmacokinetics of CYP3A4 substrates clarithromycin or quini-
dine, respectively, whereas 40  mg esomeprazole has increased the 
exposure to cisapride by 32%.15 The current study using a sensitive 
CYP3A4 index substrate midazolam indicates that the hepatic 
CYP3A4 inhibitory effect of esomeprazole, even in the highest clin-
ically used doses, is limited, probably only 25–30%, and declines to 
insignificant levels within 24 hours after dosing. Moreover, no signs 
of CYP3A4 induction were observed in any of the study phases. 
However, similarly to some studies with omeprazole,13,15,33 a slight 
induction of CYP1A2 by high-dose esomeprazole was observed in 
Figure 5 Estimation of the turnover half-life of CYP2C19 and simulation of CYP2C19 activity during and after an 8-day treatment with 
esomeprazole. (a) Estimation of the turnover half-life of CYP2C19 using a nonlinear regression model based on the recovery of the oral 
clearance (CL/F) of R-pantoprazole. A 20-mg dose of racemic pantoprazole was administered before and 1, 25, 49, and 73 hours after 
the last 80-mg dose of esomeprazole twice daily to 10 healthy volunteers. The red line represents the estimate based on the pooled 
data of the subjects. For detailed description of the regression model, see the Supplementary Table S2. Individual CL/Fs are visualized 
and CYP2C19 genotypes are denoted with different line types. (b) Simulated time course of CYP2C19 activity after time-dependent and 
reversible inhibition caused by esomeprazole and its metabolites over the course of the study. The solid green line represents the remaining 
CYP2C19 activity after 80 mg esomeprazole twice daily for 8 days based on dynamic modeling using the estimated average degradation 
rate constant (kdeg) of CYP2C19 as described in the Methods section. The thin green lines represent the 25th and the 75th percentiles 
of individual CYP2C19 degradation rate constants. The hollow circles and error bars represent the geometric mean, 25th, and 75th 
percentiles of individual CL/F values of R-pantoprazole in the 1, 25, 49, and 73 hours phases as a percentage of the CL/F in the control 
phase. CL/F values are plotted at 3 hours after the administration of the 20-mg pantoprazole dose in each phase. Dashed blue and yellow 
lines represent extrapolations of CYP2C19 activity after 40 mg or 20 mg twice daily dosing regimens, assuming linear pharmacokinetics of 
esomeprazole. t1/2, terminal half-life.



































CL/Fr = 14.0 l/h
FDCL25 = 64.3%
k = 0.013 1/h
t1/2 = 53.3 h





























ral clearance of R
-pantoprazole (%
 of control)
25. percentile (80 mg)
80 mg esomeprazole 
twice daily for 8 days
75. percentile (80 mg)
40 mg twice daily
20 mg twice daily
(a) (b)
ARTICLE
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 108 NUMBER 6 | December 2020 1263
the present study. These effects on CYP3A4 and CYP1A2 activities 
can be clinically relevant in special situations, such as with antican-
cer agents or immunosuppressants with narrow therapeutic indices, 
or with drugs that are substrates for both CYP3A4 and 2C19.
In the current study, the CYP2C19 intermediate metabolizer pheno-
type (CYP2C19*1/*2 genotype, 5/10 subjects) was over-represented, 
and CYP2C19 normal metabolizer phenotype (CYP2C19*1/*1 
genotype, 3/10 subjects) was under-represented, compared with the 
European population average.2 Thus, it is possible that the mean ef-
fect of CYP2C19 inhibition on the pharmacokinetics of panto-
prazole was smaller in the present study than it is in the general 
population with a lower frequency of no-function CYP2C19 al-
leles. Interestingly, apart from a tendency to a stronger effect of es-
omeprazole on R-pantoprazole AUC in normal/rapid CYP2C19 
metabolizers (on average, >  5-fold increase in AUC) than in 
individuals carrying the CYP2C19*2 allele, the estimated turn-
over half-life of CYP2C19 tended to be longer in normal/rapid 
CYP2C19 metabolizers than in carriers of the CYP2C19*2 allele 
(Table S3).
There are only few well-established in vivo CYP2C19 
index substrates apart from omeprazole and S-mephenytoin. 
Omeprazole was naturally not suitable for this study, and, apart 
from its clinical hazards, S-mephenytoin is not commercially 
available in Europe. Pantoprazole, the index substrate used in 
the present study, is metabolized primarily by CYP2C19 and 
to a smaller extent by CYP3A4.34 It has several advantages 
regarding pharmacokinetic studies, including good sensitiv-
ity and a short t1/2, making it suitable for repeated testing of 
transient changes in enzyme activity. In previous studies, 80 mg 
dose of pantoprazole given simultaneously with clopidogel 
has decreased the AUC of clopidogrel’s active metabolite, a 
sensitive index of CYP2C19 activity, only 14% suggesting 
negligible inhibitory effect on CYP2C19 activity at lower 
pantoprazole doses.4 Furthermore, unlike omeprazole, panto-
prazole displays similar pharmacokinetic characteristics after 
single and repeated dosing, indicating that it is not affected 
by increasing gastric pH35,36 nor is it subject to autoinhibition 
of CYP enzymes. Even a 13C-labeled pantoprazole breath test 
has been developed, providing a noninvasive method to assess 
CYP2C19.37,38 The results of the current study reinforce the 
previous finding that R-pantoprazole is a sensitive marker for 
CYP2C19 activity.17
These findings indicate that when using the highest approved 
doses, esomeprazole can be classified as a moderate to strong 
CYP2C19 inhibitor, whereas extrapolations suggested weak 
to moderate inhibition at 20 and 40  mg twice daily dosing. 
Esomeprazole has a long-lasting inhibitory effect on CYP2C19 
that can persist for at least 3–4 days following discontinuation 
of esomeprazole, indicating that irreversible inactivation is 
the main mechanism of this effect. Accordingly, even with the 
commonly used lower esomeprazole doses, care is warranted if 
a CYP2C19 substrate drug with narrow therapeutic index is 
used concomitantly or within a few days after discontinuation 
of esomeprazole. Additionally, high doses of esomeprazole cause 
a modest inhibition of CYP3A4 and induction of CYP1A2. 
Based on our estimate, the turnover half-life of CYP2C19 aver-
ages 53 hours. This estimate is useful for in vitro-in vivo extrap-
olations and physiologically-based pharmacokinetic modeling of 
drug-induced enzyme induction and mechanism-based inhibi-
tion of CYP2C19.
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